| Hodgkin Disease

Adcetris vs Leukine

Side-by-side clinical, coverage, and cost comparison for hodgkin disease.

Deep comparison between: Adcetris vs Leukine with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsLeukine has a higher rate of injection site reactions vs Adcetris based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Leukine but not Adcetris, including UnitedHealthcare

Category

Adcetris

Leukine

At A Glance

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassCD30-directed antibody-drug conjugate

RouteIV infusion or SC injection

FrequencyOnce daily

ClassGM-CSF

Indications

Hodgkin Disease
Angioimmunoblastic Lymphadenopathy
Peripheral T-Cell Lymphoma
Mycosis Fungoides
Diffuse Large B-Cell Lymphoma

Leukemia, Myelocytic, Acute
Lymphoma, Non-Hodgkin
Acute lymphocytic leukemia
Hodgkin Disease
Hematopoietic subsyndrome of acute radiation syndrome

Dosing

Hodgkin Disease (previously untreated Stage III/IV, adults) 1.2 mg/kg (max 120 mg) IV in combination with chemotherapy every 2 weeks for a maximum of 12 doses.

Hodgkin Disease (previously untreated high risk, pediatric) 1.8 mg/kg (max 180 mg) IV in combination with chemotherapy every 3 weeks for a maximum of 5 doses.

Hodgkin Disease (post-auto-HSCT consolidation) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Hodgkin Disease (relapsed) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Peripheral T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy (previously untreated) 1.8 mg/kg (max 180 mg) IV in combination with cyclophosphamide, doxorubicin, and prednisone every 3 weeks for 6 to 8 doses.

Peripheral T-Cell Lymphoma (relapsed systemic ALCL) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Mycosis Fungoides (relapsed pcALCL or CD30-expressing) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.2 mg/kg (max 120 mg) IV in combination with lenalidomide and a rituximab product every 3 weeks until disease progression or unacceptable toxicity.

Leukemia, Myelocytic, Acute 250 mcg/m2/day IV over a 4-hour period starting day 11 or four days after induction chemotherapy completion; continue until ANC >1500 cells/mm3 for 3 consecutive days or up to 42 days.

Lymphoma, Non-Hodgkin, Acute lymphocytic leukemia, Hodgkin Disease 250 mcg/m2/day IV over 24 hours or SC once daily beginning immediately following progenitor cell infusion; continue until ANC >1500 cells/mm3 for three consecutive days.

Autologous or allogeneic bone marrow transplantation 250 mcg/m2/day IV over a 2-hour period beginning 2-4 hours after bone marrow infusion; continue until ANC >1500 cells/mm3 for three consecutive days.

Delayed neutrophil recovery or graft failure 250 mcg/m2/day for 14 days as a 2-hour IV infusion; may repeat after 7 days off therapy if neutrophil recovery has not occurred, up to three courses.

Hematopoietic subsyndrome of acute radiation syndrome SC injection once daily: 7 mcg/kg for adults and pediatric patients >40 kg, 10 mcg/kg for pediatric patients 15-40 kg, 12 mcg/kg for pediatric patients <15 kg; continue until ANC >1000/mm3 for three consecutive CBCs.

Contraindications

Concomitant use with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)

History of serious allergic reactions, including anaphylaxis, to sargramostim, yeast-derived products, or any component of the product

Drug Interactions

782View drug interactions

5View drug interactions

Adverse Reactions

Most common (>=20%) Peripheral neuropathy, fatigue, nausea, diarrhea, musculoskeletal pain, pyrexia, rash, upper respiratory tract infection, constipation, alopecia

Serious Febrile neutropenia, pneumonia, hepatotoxicity, peripheral motor neuropathy, pulmonary toxicity, progressive multifocal leukoencephalopathy, tumor lysis syndrome, serious and opportunistic infections

Postmarketing Febrile neutropenia, acute pancreatitis, gastrointestinal complications, hepatotoxicity, progressive multifocal leukoencephalopathy, serious and opportunistic infections, hyperglycemia, noninfectious pulmonary toxicity including pneumonitis and ARDS, toxic epidermal necrolysis

Most common (>=10%) Fever, nausea, diarrhea, vomiting, rash, alopecia, stomatitis, asthenia, malaise, anorexia, edema, headache, chills, peripheral edema, dyspnea

Serious Hypersensitivity and anaphylaxis, infusion-related reactions, severe myelosuppression, effusions, capillary leak syndrome, supraventricular arrhythmias, leukocytosis

Postmarketing Infusion-related reactions, serious allergic reactions including anaphylaxis, effusions, capillary leak syndrome, supraventricular arrhythmias, leukocytosis including eosinophilia, thromboembolic events, injection site reactions

Pharmacology

Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of a chimeric IgG1 anti-CD30 antibody linked to MMAE, a microtubule-disrupting agent; upon binding to CD30-expressing tumor cells the ADC is internalized and MMAE is released via proteolytic cleavage, disrupting the microtubule network within the cell and inducing cell cycle arrest and apoptosis.

Sargramostim (GM-CSF) is a colony-stimulating factor that supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells, inducing partially committed progenitors to divide and differentiate into granulocyte-macrophage pathways including neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells; it can also activate mature granulocytes and macrophages and promote proliferation of megakaryocytic and erythroid progenitors.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Adcetris